Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Letrozole vs Chemotherapy in Neoadjuvant ER+ Breast Cancer
NCT04137640Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jul 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of palbociclib in breast cancer, sponsored by Shengjing Hospital of China Medical University. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04137640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137640.